These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 17371238)

  • 1. Isoform-selective PI3K inhibitors as novel therapeutics for the treatment of acute myocardial infarction.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Hood J; Soll R
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):204-6. PubMed ID: 17371238
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aerosolized phosphoinositide 3-kinase gamma/delta inhibitor TG100-115 [3-[2,4-diamino-6-(3-hydroxyphenyl)pteridin-7-yl]phenol] as a therapeutic candidate for asthma and chronic obstructive pulmonary disease.
    Doukas J; Eide L; Stebbins K; Racanelli-Layton A; Dellamary L; Martin M; Dneprovskaia E; Noronha G; Soll R; Wrasidlo W; Acevedo LM; Cheresh DA
    J Pharmacol Exp Ther; 2009 Mar; 328(3):758-65. PubMed ID: 19056934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of 3,3'-(2,4-diaminopteridine-6,7-diyl)diphenol as an isozyme-selective inhibitor of PI3K for the treatment of ischemia reperfusion injury associated with myocardial infarction.
    Palanki MS; Dneprovskaia E; Doukas J; Fine RM; Hood J; Kang X; Lohse D; Martin M; Noronha G; Soll RM; Wrasidlo W; Yee S; Zhu H
    J Med Chem; 2007 Sep; 50(18):4279-94. PubMed ID: 17685602
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phosphoinositide 3-kinase signalling in the vascular system.
    Morello F; Perino A; Hirsch E
    Cardiovasc Res; 2009 May; 82(2):261-71. PubMed ID: 19038971
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Advantages of a selective beta-isoform phosphoinositide 3-kinase antagonist, an anti-thrombotic agent devoid of other cardiovascular actions in the rat.
    Sturgeon SA; Jones C; Angus JA; Wright CE
    Eur J Pharmacol; 2008 Jun; 587(1-3):209-15. PubMed ID: 18455722
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biological effects of isoform-specific PI3-kinase inhibition.
    Ihle NT; Powis G
    Curr Opin Drug Discov Devel; 2010 Jan; 13(1):41-9. PubMed ID: 20047145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Therapeutic potential of phosphatidylinositol 3-kinase inhibitors in inflammatory respiratory disease.
    Ito K; Caramori G; Adcock IM
    J Pharmacol Exp Ther; 2007 Apr; 321(1):1-8. PubMed ID: 17021257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phosphoinositide 3-kinase delta inhibitor as a novel therapeutic agent in asthma.
    Park SJ; Min KH; Lee YC
    Respirology; 2008 Nov; 13(6):764-71. PubMed ID: 18811876
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemically targeting the PI3K family.
    Knight ZA; Shokat KM
    Biochem Soc Trans; 2007 Apr; 35(Pt 2):245-9. PubMed ID: 17371250
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PI3K delta and PI3K gamma: partners in crime in inflammation in rheumatoid arthritis and beyond?
    Rommel C; Camps M; Ji H
    Nat Rev Immunol; 2007 Mar; 7(3):191-201. PubMed ID: 17290298
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Furan-2-ylmethylene thiazolidinediones as novel, potent, and selective inhibitors of phosphoinositide 3-kinase gamma.
    Pomel V; Klicic J; Covini D; Church DD; Shaw JP; Roulin K; Burgat-Charvillon F; Valognes D; Camps M; Chabert C; Gillieron C; Françon B; Perrin D; Leroy D; Gretener D; Nichols A; Vitte PA; Carboni S; Rommel C; Schwarz MK; Rückle T
    J Med Chem; 2006 Jun; 49(13):3857-71. PubMed ID: 16789742
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI-3 kinase for treating respiratory disease: good idea or bad idea?
    Thomas M; Owen C
    Curr Opin Pharmacol; 2008 Jun; 8(3):267-74. PubMed ID: 18394961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Antiangiogenic effect of ZSTK474, a novel phosphatidylinositol 3-kinase inhibitor.
    Kong D; Okamura M; Yoshimi H; Yamori T
    Eur J Cancer; 2009 Mar; 45(5):857-65. PubMed ID: 19144509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting the PI3K p110alpha isoform inhibits medulloblastoma proliferation, chemoresistance, and migration.
    Guerreiro AS; Fattet S; Fischer B; Shalaby T; Jackson SP; Schoenwaelder SM; Grotzer MA; Delattre O; Arcaro A
    Clin Cancer Res; 2008 Nov; 14(21):6761-9. PubMed ID: 18980969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phosphoinositide 3-kinase gamma/delta inhibition limits infarct size after myocardial ischemia/reperfusion injury.
    Doukas J; Wrasidlo W; Noronha G; Dneprovskaia E; Fine R; Weis S; Hood J; Demaria A; Soll R; Cheresh D
    Proc Natl Acad Sci U S A; 2006 Dec; 103(52):19866-71. PubMed ID: 17172449
    [TBL] [Abstract][Full Text] [Related]  

  • 16. PI3K inhibitors in cardiovascular disease.
    Eisenreich A; Rauch U
    Cardiovasc Ther; 2011 Feb; 29(1):29-36. PubMed ID: 20626398
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atorvastatin enhances interleukin-10 levels and improves cardiac function in rats after acute myocardial infarction.
    Stumpf C; Petzi S; Seybold K; Wasmeier G; Arnold M; Raaz D; Yilmaz A; Daniel WG; Garlichs CD
    Clin Sci (Lond); 2009 Jan; 116(1):45-52. PubMed ID: 18459941
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protease-activated receptor-2 stimulates intestinal epithelial chloride transport through activation of PLC and selective PKC isoforms.
    van der Merwe JQ; Moreau F; MacNaughton WK
    Am J Physiol Gastrointest Liver Physiol; 2009 Jun; 296(6):G1258-66. PubMed ID: 19359428
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of phosphoinositide 3-kinase p110 delta in TLR4- and TLR9-mediated B cell cytokine production and differentiation.
    Dil N; Marshall AJ
    Mol Immunol; 2009 Jun; 46(10):1970-8. PubMed ID: 19362372
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phosphoinositide 3-kinase gamma inhibition plays a crucial role in early steps of inflammation by blocking neutrophil recruitment.
    Ferrandi C; Ardissone V; Ferro P; Rückle T; Zaratin P; Ammannati E; Hauben E; Rommel C; Cirillo R
    J Pharmacol Exp Ther; 2007 Sep; 322(3):923-30. PubMed ID: 17526805
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.